In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $54.74 down -2.20% from its previous closing price of $55.97. In other words, the price has decreased by -$2.20 from its previous closing price. On the day, 1.16 million shares were traded. CRSP stock price reached its highest trading level at $58.0 during the session, while it also had its lowest trading level at $54.61.
Ratios:
For a deeper understanding of CRISPR Therapeutics AG’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.22 and its Current Ratio is at 16.22. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In the most recent recommendation for this company, JP Morgan on September 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On February 14, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $60 to $99.
TD Cowen Upgraded its Sell to Hold on February 12, 2025, while the target price for the stock was maintained at $35.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 17 ’25 when Kulkarni Samarth sold 50,895 shares for $67.91 per share. The transaction valued at 3,456,279 led to the insider holds 254,201 shares of the business.
Kulkarni Samarth sold 4,242 shares of CRSP for $282,517 on Oct 14 ’25. The Chief Executive Officer now owns 205,096 shares after completing the transaction at $66.60 per share. On Oct 14 ’25, another insider, KASINGER JAMES R., who serves as the General Counsel and Secretary of the company, sold 1,076 shares for $66.60 each. As a result, the insider received 71,662 and left with 83,402 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5216734720 and an Enterprise Value of 3512048640. For the stock, the TTM Price-to-Sale (P/S) ratio is 136.06 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 91.61 whereas that against EBITDA is -7.643.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.68, which has changed by 0.38591063 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $78.48, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -8.43%, while the 200-Day Moving Average is calculated to be 7.38%.
Shares Statistics:
For the past three months, CRSP has traded an average of 2.46M shares per day and 1723120 over the past ten days. A total of 93.87M shares are outstanding, with a floating share count of 91.51M. Insiders hold about 3.98% of the company’s shares, while institutions hold 71.44% stake in the company. Shares short for CRSP as of 1764288000 were 22431985 with a Short Ratio of 9.12, compared to 1761868800 on 21033230. Therefore, it implies a Short% of Shares Outstanding of 22431985 and a Short% of Float of 26.419999999999998.
Earnings Estimates
At present, 17.0 analysts are actively evaluating the performance of CRISPR Therapeutics AG (CRSP) in the stock market.The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.87 and low estimates of -$1.25.
Analysts are recommending an EPS of between -$4.97 and -$6.86 for the fiscal current year, implying an average EPS of -$6.2. EPS for the following year is -$4.46, with 19.0 analysts recommending between -$2.0 and -$6.22.
Revenue Estimates
A total of 23 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $27.6M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $6.12M. In the same quarter a year ago, actual revenue was $37.31M
